CDK8-IN-19

CDK8-IN-19 (Compound 3d) is a CDK8 inhibitor with an IC50 of 25.08 nM. CDK8-IN-19 has a broad-spectrum anticancer activity, such as leukemia, melanoma and breast cancer, without significant cytotoxic effect on the normal Vero cells (mean IC50s of 2.87, 3.65, 3.79 and 45.48 μM, respectively) [1].

Product Specifications

UNSPSC

12352005

Target

CDK; PI3K

Related Pathways

Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

S=C(NC1=CC=C(Cl)C=C1Cl)NC(S/C2=C/C3=CC=CC=C3)=NC2=O

Molecular Formula

C17H11Cl2N3OS2

Molecular Weight

408.32

References & Citations

[1]Mohamed AR, et al. Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents. Eur J Med Chem. 2025 Oct 15;296:117902.